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initiating therapy (Indian Journal of Psychiatry, 
1999, 41,1, 81-82). Acute dystonia is reported 
to have occured in early part of therapy with 
commonly used psychopharmacological agents 
(Kuruvilla & Kuruvilla, 1995) but no case of 
akathisia was observed in a multicenter trial of 
risperidone in Indian patients with schizophrenia 
(Agarwal et al.,1998). Occurence of EPS in 
patients receiving risperidone is said to be dose 
related and it has a reduced propensity to cause 
akathisia (Owens, 1996). Therefore the author's 
observation of acute dystonia and akathisia 
deserves attention and a careful observation for 
EPS in patients receiving risperidone, is required. 
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REPLY 
Sir, 
I am grateful to Dr.S.K.Pandey for his 
interest and valuable comment on the article 
"Risperidone induced dystonia and akathisia". 
Though risperidone is reported to have a broad 
spectrum of antipsychotic activitity it has a 
differential side effect profile at different doses. At 
a dose of 6 mg per day, risperidone demonstrates 
higher 5-HT2 (80-100%) than D2 (74-83%) 
occupancy bordering on the extrapyramidal 
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threshold. At this dose the presence of potent 
5-HT2 antagonism may reduce risperidone's risk 
of E.P.S. in comparison with conventional 
antipsychotics. As the dose of risperidone is 
increased beyond 6 mg/day suprathreshold D2 
blockade may result and the balanced serotonin 
dopamine interaction may no longer be able to 
alleviate extrapyramidal symptoms (Kapur & 
Remington, 1996). Marder et al. (1994) in a study 
of assessment of the efficacy of risperidone in the 
treatment of schizophrenia did not find any 
significant difference in extrapyramidal symptom 
rating scale score between patients who received 
placebo and < 6 mg of risperidone. However, in 
the index case report Mr.B was receiving only 6 
mg of risperidone per day still he experienced 
dystonic reaction and intractable akathesia which 
was not relieved by propranolol 120 mg/day. One 
possible reason for the expression of these side 
effects at a "safer therapeutic window" could be 
due to racial changes in the pharmacokinetics and 
pharmacodynamic profile of patients in India 
making them more susceptible to extrapyramidal 
side effects. May be our patients achieving higher 
D2 occupancy at a lower therapeutic dose. In 
contradiction to Dr.S K.Pandey's comment, 14 
(8.5%) cases of akathisia has been reported in the 
multicenter trial of risperidone in Indian patients 
with schizophrenia at the end of 6 weeks therapy 
(Agarwal etal., 1998). In the same series 8 (10.9%) 
patients had rigidity, 29 (17.6%) had hypokinesia 
and 37 (22.4%) had tremor at the end of trial. Out 
of 146 patients 75 received only 6 mg risperidone 
per day. A separate analysis of this two group of 
patients might have given more information about 
the relationship between risperidone's dose and 
extrapyramidal side effects. 
A single case report can only serve to 
stimulate interest in further study. Future studies 
concurrently assessing plasma level, receptor 
occupancy and side effects can answer this 
therapeutic problem. 
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CATATONIC SYNDROME : TREATMENT 
RESPONSE TO LORAZEPAM 
Sir, 
We read with interest the study by Payee 
et al. (1999). Authors remark that no study on the 
treatment of catatonia with lorazepam has been 
carried out in India. In this context, we would like 
to mention that a similar but more exhaustive 
study has been conducted by us on a larger patient 
population at Central Institute of Psychiatry, 
Ranchi. We share a few findings from our study, 
which is currently in the process of publication. 
Our study had 60 patients who were divided 
into four treatment groups- low dose (4 mg/day) 
and high dose (8 mg/day) oral lorazepam and 
low dose (4 mg/day) and high dose (8 mg/day) 
intravenous lorazepam. Besides using the Bush-
Francis Catatonia Screening Instrument and the 
Bush-Francis Catatonia Rating Scale (BFCRS), 
Brief Psychiatric Rating Scale (BPRS) was also 
used to assess the psychopathology. Some of our 
findings concurred with the findings of the 
aforementioned study. For instance, we found 
more patients with schizophrenia as well as acute 
and transient psychotic disorders than affective 
disorders presenting with catatonic syndrome. 
Moreover, severity and duration of catatonia did 
not predict the response to treatment with 
lorazepam. However, there were other results, 
which were at variance with the authors' study. 
We observed that treatment response after 72 
hours of treatment with lorazepam was the best 
predictor of the final treatment outcome. 
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Furthermore, although response to lorazepam did 
not vary significantly across the different 
psychiatric diagnoses, patients with acute and 
transient psychotic disorders did show greater 
improvement. 
A new finding was the positive correlation 
between psychopathology based on BPRS scores 
before treatment and the severity of catatonia. 
However, there was no correlation between BPRS 
scores before treatment and the scores of 
catatonia on BFCRS following treatment. This 
indicated that the severity of psychopathology did 
not have any predictive value in the therapeutic 
response of lorazepam in catatonia. Other novel 
findings not alluded to before in the available 
literature included the faster onset of action of 
intravenous lorazepam in comparison to oral 
lorazepam. There was a significant difference 
between the oral and parenteral groups after half 
an hour of treatment. This may be attributed to 
difference in pharmacokinetics between the two 
routes of lorazepam administration. However, the 
treatment response did not differ between the two 
groups after 96 hours of treatment. Moreover, 
response of catatonic signs to low dose and high 
dose lorazepam did not differ significantly in either 
the oral or the parenteral group. 
Although our study is of open-label design, 
nevertheless it allows a few tentative conclusions. 
First, schizophrenia along with acute and transient 
psychotic disorders remain a dominant cause of 
catatonic syndrome in India, which differs from 
western studies implicating affective disorders as 
the main cause (Rosebush et al., 1990; Bush et 
al.,1996). Second, an initial dramatic 
improvement in catatonic symptomatology on 
parenteral lorazepam has no predictive value in 
ascertaining future response to it. Third, over a 
period of four days, there is no significant 
difference in response of catatonic signs to oral 
or parenteral lorazepam. Finally, no additional 
benefit is accrued by giving higher doses of 
lorazepam in the treatment of catatonic syndrome. 
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